Blood:FcRn可放大IgG免疫复合物对组织因子活性的诱导

2020-03-21 MedSci原创 MedSci原创

新生的IgG Fc受体,FcRn,参与包含IgG的免疫复合物介导的组织因子活性的诱导。抑制FcRn或可减轻由包含IgG的免疫复合物所介导的疾病患者的血栓形成前表现。

血栓栓塞使由含IgG的免疫复合物(IC)引起的疾病复杂化,但其潜在机制尚未完全了解。既往研究表明,IC引发凝血启动、定位和传播的关键步骤——单核细胞组织因子(TF)诱导,是通过Fcγ受体IIa(FcγRIIa)介导,但其他受体的参与情况尚无详细研究。

介导IgG和白蛋白循环的新生Fc受体(FcRn)也参与对含IgG的IC的细胞反应。FcRn是否也参与THP-1单核细胞和人单核细胞通过IgG-ICs所介导的TF依赖性Xa因子活性的诱导?研究人员对此进行研究。

包含抗血小板因子F(PF4,与肝素诱导性血小板减少症[HIT]相关)的IgG抗体、b-2-糖蛋白-1(与抗磷脂抗体综合征[APS]相关)或红细胞的抗α-Rh(D)抗体(介导体内溶血)的ICs所介导的Xa因子活性诱导可被人源化单克隆抗体(MoAb)抑制,该抗体可阻断IgG与人FcRn结合。

与FcγR和FcRn结合的IgG ICs诱导Xa因子活性,而Fc被改造后的IgG-ICs不能与FcRn结合,也不能诱导Xa因子活性。在表达人FcgRIIa的HIT转基因小鼠模型中,注射α-FcRn MoAb可防止微血管损伤后纤维蛋白沉积。

本研究结果表明FcRn具有可溶性和细胞相关性含IgG的IC诱导的TF依赖性FXa活性。目前,在热自身免疫溶血性贫血的临床试验中,FcRn抗体可降低IgG抗体和含IgG的ICs,还可以降低静脉血栓栓塞的风险。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
    2021-02-25 zgwhgch
  5. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1910657, encodeId=c4f0191065e38, content=<a href='/topic/show?id=b45b426195e' target=_blank style='color:#2F92EE;'>#复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42619, encryptionId=b45b426195e, topicName=复合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ad7f282, createdName=yang0210, createdTime=Thu Nov 26 16:58:52 CST 2020, time=2020-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005724, encodeId=c2ec2005e24b6, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Apr 17 19:58:52 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664393, encodeId=22ac166439323, content=<a href='/topic/show?id=308be767080' target=_blank style='color:#2F92EE;'>#组织因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77670, encryptionId=308be767080, topicName=组织因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb9e25754903, createdName=12498bf3m33暂无昵称, createdTime=Sat Oct 10 14:58:52 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968667, encodeId=31ca196866e65, content=<a href='/topic/show?id=a56ae28167' target=_blank style='color:#2F92EE;'>#FcRn#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7281, encryptionId=a56ae28167, topicName=FcRn)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Thu Feb 25 00:58:52 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522259, encodeId=e1761522259f8, content=<a href='/topic/show?id=83732900161' target=_blank style='color:#2F92EE;'>#免疫复合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29001, encryptionId=83732900161, topicName=免疫复合物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=311711435936, createdName=zhaohui6735, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1615212, encodeId=969816152125d, content=<a href='/topic/show?id=010c9506a3' target=_blank style='color:#2F92EE;'>#IgG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9506, encryptionId=010c9506a3, topicName=IgG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c4f19588882, createdName=ms5768352621950538, createdTime=Mon Mar 23 10:58:52 CST 2020, time=2020-03-23, status=1, ipAttribution=)]

相关资讯

Blood:抗凝药物不能阻断组织因子和血小板触发的静脉血栓形成

中心点:抗凝血酶和C蛋白被抑制后,组织因子和血小板是小鼠静脉血栓形成的限速因子。在本动物模型中,凝血因子XII和循环中的中性粒细胞不限制静脉血栓形成的速度。摘要:组织因子、凝血因子XII、血小板和中性粒细胞在静脉血栓形成(VT)的病理生理过程中具有重要作用。在需要手术处理才能诱发VT的小鼠模型中,它们的作用变得很明显。在小鼠中,仅采用小干扰RNA(siRNA)联合抑制天然抗凝血剂抗凝血酶(Serp

Blood:促血管生成的PAR2信号通路需要凝血因子VIIa整合素结合位点的参与。

组织因子(TF)通路既可以发挥止血作用,也可发挥细胞信号传递的作用,但细胞如何控制TF的不同功能尚不完全了解。TF是清除蛋白酶激活受体(PAR)2的凝血酶的受体和支架,在血管生成和肿瘤形成过程中发挥关键作用。研究人员发现凝血因子VIIa不依赖可替代的PAR2激活剂蛋白裂解酶,即可诱发TF胞质内结构域依赖性的促血管生成的细胞信号通路。TF-FVIIa复合物与整合素β1的活性异构体相结合,需要FVII

Nature:组织因子和PAR1促进肠道菌群诱导的血管重塑

瑞典哥德堡大学Sahlgrenska学院研究人员发现了肠道细菌影响血管形成的一种以前未知的机制。相关结果发表在《自然》杂志上,研究结果可能为未来肠道疾病和肥胖的治疗提供新思路。 我们的肠道细菌数量是人体细胞数量的十倍以上。然而,我们很少知道肠道菌群的功能以及这些菌群对我们生理上产生什么样的影响。 以前未知的机制 在小鼠动物模型的研究中,研究人员发现了肠道菌群如何影响肠道生理和血管重塑的以

NEJM:血栓性微血管病全新诊疗进展

血栓性微血管病 (thrombotic microangiopathy,TMA) 是一组具有共同病理特征的急性临床病理综合征,分为遗传性和获得性,主要表现为内皮细胞肿胀脱落、内皮下绒毛状物质沉积和血管腔内血小板聚集形成微血栓、血管腔内栓塞及红细胞碎裂等微血管系统异常。 TMA临床上主要表现为血小板减少、溶血性贫血和微循环中血小板血栓造成的器官受累,其临床表现与TMA 的病变范围和累及不同器官

Blood:酸性鞘磷脂酶在LPS和细胞因子诱导组织因子促凝活性中的作用

组织因子(TF)是VIIa因子的辅因子,是凝血的主要细胞诱发因子。通常情况下,细胞表面的TF大多以一种神秘的、凝血不活跃状态存在,但在细胞活化后会转化为促凝状态(解码/解密)。